1-(3-氟苯基)哌嗪，CAS 登记号 3801-89-6，由济南圣和化工有限公司现货供应，可提供纯度 按批次COA提供(不公开发布) 的规格，下游主要用于有机化学品。支持样品与小批量试用，批量价格请联系我们获取，验收以批次 COA 为准。
有机化学品
每批随货提供 COA；可按需提供 MSDS 及技术文件。邮件注明产品名称与 CAS 号，一个工作日内回复报价。
本页已列出 1-(3-氟苯基)哌嗪 的 CAS 号：3801-89-6，可与随货 COA 核对。
常见纯度为 按批次COA提供(不公开发布)，包装形式为 按订单/批次确认(不公开发布)，特殊规格可在询价时说明。
主要涉及有机化学品。
来信 info@591daili.com 或 WhatsApp 联系，提供产品名称、CAS 号与数量，确认价格与交期后即可安排发货，验收以批次 COA 为准。
1-(3-fluorophenyl)piperazine · CAS 3801-89-6 · C10H13FN2. UNII B46UBR8BEE.
| CAS Registry Number | 3801-89-6 |
|---|---|
| PubChem CID | 77418 |
| Molecular formula | C10H13FN2 |
| IUPAC name | 1-(3-fluorophenyl)piperazine |
| UNII (FDA) | B46UBR8BEE |
| Molecular Weight | 180.22 |
|---|---|
| XLogP3 | 1.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Exact Mass | 180.10627659 |
| Monoisotopic Mass | 180.10627659 |
| Topological Polar Surface Area | 15.3 |
| Heavy Atom Count | 13 |
| Formal Charge | 0 |
| Reported hazard statements | H302 (100%), H312 (33.3%), H315 (33.3%), H319 (33.3%), H332 (33.3%), H335 (33.3%), H412 (66.7%) |
|---|
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
H312 (33.3%): Harmful in contact with skin [Warning Acute toxicity, dermal]
1-(3-Fluorophenyl)piperazine; 3801-89-6; Piperazine, 1-(3-fluorophenyl)-; B46UBR8BEE; EINECS 223-271-9; N-(3-Fluorophenyl)piperazine; DTXSID40191426; 1-(M-FLUOROPHENYL)PIPERAZINE; PIPERAZINE, 1-(M-FLUOROPHENYL)-; RefChem:423859; DTXCID50113917; 223-271-9; Piperazine,1-(3-fluorophenyl)-; 1-(3-fluorophenyl)-piperazine; C10H13FN2; MFCD03412122
CAS 3801-89-6; molecular formula C10H13FN2; molecular weight — g/mol.
1-(3-Fluorophenyl)piperazine, 3801-89-6, Piperazine, 1-(3-fluorophenyl)-, B46UBR8BEE, EINECS 223-271-9, N-(3-Fluorophenyl)piperazine.
Hazard statements reported: H302, H312, H315, H319, H332.
Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.